To determine the agreement and correlation of visual acuity between Rapid Eye Screening Test (REST) app and Early Treatment Diabetic Retinopathy Study (ETDRS) tumbling 'E' chart. Methods: A visual acuity tool was designed for Android and iOS users based on ETDRS. A pilot study was conducted involving 101 subjects. Visual acuity of each subject was tested using ETDRS chart and crossover to REST at 3 meters or vice versa. Results: Mean visual acuity using ETDRS was 0.086 9 0.194 for right eye (RE) and 0.085 9 0.196 for left eye (LE) while REST measurement was 0.091 9 0.182 for RE and 0.098 9 0.203 for LE. There was significant and strong direct correlation between visual acuity using ETDRS and REST in both eyes (RE: r 0 0.829; p B 0.001, LE: r 0 0.871; p B 0.001). The 95% limits of agreement between the two charts was 90.11 LogMAR for right eye and 90.10 LogMAR for left eye. Time taken for REST was significantly shorter than ETDRS (p B 0.001). Conclusion: REST is accurate and time-saving, thus potentially ideal for mass screening in remote area.

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease that can affect any part of the human body including the eyes. Common blinding ocular manifestations include central retinal artery occlusion (CRAO), central retinal vein occlusion (CRVO), severe vaso-occlusive retinopathy, and optic nerve involvement. Antiphospholipid syndrome (APS) in lupus is usually associated with large vessel occlusions and needs prompt treatment with anticoagulant. We are reporting two cases of APS in SLE patients that presented with CRVO (case 1) and vaso-occlusive lupus retinopathy (case 2). Both cases were positive for antiphospholipid antibody (APA) and were treated with immunosuppression, anticoagulant, and laser treatment. Thus, screening for APA is vital in SLE patients with lupus retinopathy, as prompt treatment with anticoagulants is important to prevent further vascular thrombosis, which worsens the visual prognosis.